期刊文献+

MRP与肺癌分化程度、临床分期、淋巴结转移关系的Meta分析 被引量:5

A Meta-analysis on the Relationship between MRP and Differentiation Level,TNM stages and Lymph Node Metastasis of Lung Cancer
下载PDF
导出
摘要 目的从循证医学角度综合分析MRP(多药耐药相关蛋白)与肺癌分化程度、临床分期、淋巴结转移的相关性,预测肺癌化疗的预后。方法采用Meta分析对有关MRP与人肺癌分化程度、TNM分期、淋巴结转移的文献进行综合分析。结果共纳入16个研究,MRP在低分化肺癌组织中的阳性表达率是高分化组织的1.62倍[OR=1.62,95%CI(1.29,2.04)];在Ⅲ-Ⅳ期肺癌组织中的阳性表达率是Ⅰ-Ⅱ期的1.54倍[OR=1.54,95%CI(1.23,1.93)];而与有无淋巴结转移无相关性[OR=0.84,95%CI(0.55,1.27)]。结论 MRP的表达与肺癌组织的分化程度及临床分期存在一定的相关性,而与有无淋巴结转移无关,提示MRP可能成为一项判断肺癌预后的指标。 【Objective】 To understand the relationship between multidrug-resistance protein(MRP) and differentiation level,TNM stages and lymph node metastasis of lung cancer based on evidence-based medicine and predict the prognosis of chemotherapy.【Methods】 Comprehensively analyzed the literatures about differentiation level,TNM stages and lymph node metastasis of lung cancer.【Results】 16 studies were included.Expression level of MRP in poorly differentiated cancer tissue is 1.62 times than that in well-differentiated tissue,in Ⅲ-Ⅳstage cancer tissue is 1.54 times than that in Ⅲ-Ⅳstage tissue,while there was no relevance between MRP and lymph node metastasis.【Conclusion】 The expression of MRP has relationship with differentiation level and TNM stages,no relationship with lymph node metastasis,which indicate that MRP may determine the prognosis of lung cancer.
出处 《中国医学工程》 2011年第7期27-29,32,共4页 China Medical Engineering
基金 辽宁省教育厅(基金编号:05L469)
关键词 MRP(多药耐药相关蛋白) 肺癌 分化程度 TNM分期、淋巴结转移 META分析 multidrug-resistance protein(MRP) lung cancer differentiation level TNM stages lymph node metastasis Meta-analysis
  • 相关文献

参考文献12

二级参考文献112

  • 1彭忠民,罗静,王潍博,王晓航,陈景寒,兰守敏.耐药相关基因表达对Ⅲ期非小细胞肺癌新辅助化疗的临床预测价值探讨[J].癌症,2004,23(8):963-967. 被引量:7
  • 2周承志,李勇,徐军.肺癌组织p53基因突变与肿瘤耐药基因表达的相关性及其临床意义[J].中华结核和呼吸杂志,2004,27(10):678-682. 被引量:8
  • 3左云,黄建安,穆传勇,沈冬.耐药相关基因MDR1、MRP、LRP及其表达产物P-gp、MRP、LRP在非小细胞肺癌组织中的表达及意义[J].临床肿瘤学杂志,2006,11(12):921-928. 被引量:13
  • 4Pujol JL,Simony J,Gautier V,et al. Immunohistoehemieal study of P-glyeoprotein distribution in lung caneer. Lung Caneer, 1993; 10(1):1-12.
  • 5Chaudhary PM,Roninson IB. Expression and activity of P-glycoprotein a multi-drug efflux pump in human hematopoietic stem cells.Cell,1991;66:85.
  • 6Galimberti S, Marcetti A, Buttitta F,et al. Multi-drug resistance related genes and P53 expression in human non-small cell lung cancer. Anticancer Res,1998-18:2973-297.
  • 7Beer TW, Rowlands DC, Crocker J, et al. Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumors. Thorax,1996-51:526-29.
  • 8Izquierdo MA,Shoemaker RH,Fkens MJ,et al. Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer,1996,65(2):422-426.
  • 9Blanc E, Goldschneider D, Ferrandis E, et al. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model [J]. Am J Pathol, 2003, 163(1):321-331.
  • 10Latil A,Vidaud D,Valeri A, et al. hTERT expression correlates with MYC over-expression in human prostate cancer [J]. Int J Cancer, 2000, 89(2) : 172-176.

共引文献70

同被引文献106

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部